NR3C1 and inflammatory bowel disease: In the present study, we conducted comprehensive bioinformatics analyses around GR and TET2 regulation as well as established in vitro inflammatory models with different baseline levels of GR expression, ultimately identifying BMS-536924 as a potential small-molecule drug for IBD.